Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Single Blinded Ivig

Research Leaders

6 sponsors active, led by University of Texas Southwestern Medical Center

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01522235Phase 2/3CompletedPrimary

Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

Showing all 1 trials

Research Network

Common Treatments

  • Single Blinded Ivig1
  • Double Blinded Placebo1
  • Double Blinded Ivig1

Active Sponsors

  • University of Texas Southwestern Medical Center1
  • Vanderbilt University1
  • Beth Israel Deaconess Medical Center1
  • National Institute of Neurological Disorders and Stroke (NINDS)1
  • NYU Langone Health1

Top Investigators

Activity Timeline